[Federal Register Volume 76, Number 51 (Wednesday, March 16, 2011)]
[Notices]
[Pages 14417-14418]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-6124]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice of intent to grant exclusive license.
-----------------------------------------------------------------------
SUMMARY: Pursuant to 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i),
this will serve to notify the public that the National Institutes of
Health, Department of Health and Human Services, is contemplating the
grant of an exclusive patent license to intellectual property broker
ICAP Ocean Tomo to promote the utilization by the public of the
inventions described in the following U.S. patents: 7,122,624
[[Page 14418]]
entitled ``PH2 Receptor Ligands'' (HHS Ref. No. E-123-1999/0), and
7,087,736 entitled ``Tyrosine DNA phosphodiesterases (TDP) and related
polypeptides, nucleic acids, vectors, TDP producing host cells,
antibodies and methods of use'' (HHS Ref. No. E-281-1999/0). The patent
rights in this invention have been assigned to the United States of
America.
The prospective exclusive license territory may be worldwide and
the field of use may be for the use of the Licensed Patent Rights in
developing biopharmaceutical products.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
March 31, 2011 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated exclusive
license should be directed to: Mojdeh Bahar, J.D., Chief, Cancer
Branch, Office of Technology Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804;
Telephone: (301) 435-2950; Facsimile: (301) 402-0220; E-mail:
[email protected].
SUPPLEMENTARY INFORMATION: Prior to March 31, 2011, with NIH's explicit
prior consent, ICAP will advertise the availability of the NIH
technologies for licensing. Bidders may bid at anytime. Before any bid
is accepted, NIH will review the commercial development plan (CDP) and
assess the suitability of the bidder as a licensee.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless within
fifteen(15) days from the date of this published notice, the NIH
receives written evidence and argument that establishes that the grant
of the license would not be consistent with the requirements of 35
U.S.C. 209 and 37 CFR 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: March 9, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2011-6124 Filed 3-15-11; 8:45 am]
BILLING CODE 4140-01-P